Osaka-Based Sakai Chemical Industrial Expands Contract Pharmaceutical Production
This article was originally published in PharmAsia News
Osaka-based drug maker Sakai Chemical Industrial will boost its Nagano, Osaka factory's capacity and operation rates with plans to expand its contract drug production business. Currently contracted by four pharmaceutical companies, Sakai produces 10 therapeutic and 25 over-the-counter drugs, with 1 million solid preparations and 100,000 liquid formulations per month. Sakai plans to increase the capacity to 2 million solids and 500,000 liquids and increase to 10 contract companies. The company also plans to be manufacture sprays, oral solutions and health foods. The company expects the income from the contract production business will increase to ¥1 billion from several hundred thousand yen. (Click here for more - Japanese language
You may also be interested in...
A proposed rule released last month by the US Department of Health and Human Services is the Trump administration’s “latest attempt to sabotage HHS programs,” wrote Jessica Schubel, a senior policy analyst for the Center on Budget and Policy Priorities. See what the policy expert said about it in her blog post here.
Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.
White House and HHS are increasing pressure on FDA Commissioner Hahn to clear Pfizer and Moderna’s COVID-19 vaccines as soon as possible – potentially skirting the advisory committee process. The move is leaving a last-minute political stain on a regulatory process the FDA fought hard to keep science-based and could foster a new wave of vaccine hesitancy amongst the American public.